Abstract 4370781: Membrane-Repairing LncRNA Masir Protects the Heart from Ischemic Injury

Background: Cardiomyocytes (CMs) undergo constant mechanical stress during contraction and are vulnerable to membrane damage. Impaired sarcolemmal integrity is a key factor of heart failure progression; hence, strengthening membrane repair represents a promising strategy for cardioprotection. While long non-coding RNAs (lncRNAs) are pivotal in cardiac function and disease, their direct involvement in membrane repair remains largely unexplored. Objective: To identify lncRNAs involved in membrane repair and evaluate their therapeutic potential in ischemic cardiac injury. Methods: Subcellular RNA fractionation (cytosolic, organellar, and plasma membrane) were isolated from heart tissues and sequenced to identify lncRNAs enriched at the plasma membrane (PM). Top candidate lncRNAs were assessed for their role in endocytosis, exocytosis and membrane repair using HL-1 cardiac muscle cells, neonatal CMs, and human induced pluripotent stem cell (iPSC)-differentiated CMs. Intramuscular delivery of lncRNAs was used to evaluate their therapeutic effect in a mouse model of myocardial infarction (MI). Results: Of the top 30 candidate lncRNAs, five PM-enriched lncRNAs were successfully cloned, synthesized, and purified, including Masir (MG53-associated sarcolemma injury repair lncRNA). Gfp RNA served as a control. Masir enhanced both endocytosis and exocytosis in HL-1 cardiac muscle cells. Importantly, rapid extracellular treatment of Masir significantly reduced laser-induced membrane injuries in HL-1 cells and wild-type neonatal CMs but had no effect in MG53-knockout CMs. In vivo, Masir -treated mice demonstrated improved cardiac function post-MI compared to Gfp -treated controls, with higher ejection fraction (34.29% ± 5.36, n=13 vs. Gfp : 21.53% ± 2.64, p =0.047) and significantly smaller scar size. Notably, mouse Masir RNA also attenuated laser-induced membrane injury in hiPSC-derived CMs, highlighting its translational relevance. Conclusion: Masir interacts with MG53, promotes sarcolemmal membrane repair, and confers protection against ischemic injury. These finding demonstrate a direct, functional role for lncRNAs in membrane repair and establish a foundation for RNA-based therapies targeting heart disease.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4370781
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4370781: Membrane-Repairing LncRNA Masir Protects the Heart from Ischemic Injury

Ji‐Dong Fu, Kassidy Banford, Chunlei Guo, Thomas J. Hund et al.
Circulation
Cancer-related molecular mechanisms research
article

Abstract 4370781: Membrane-Repairing LncRNA Masir Protects the Heart from Ischemic Injury

Ji‐Dong Fu, Kassidy Banford, Chunlei Guo, Thomas J. Hund, Snizhana Chorna, Hua Zhu, Nawal Tamimi, Xianyao Xu, Noah Weisleder, G. Giarrano, Feng Tang, Isabelle Deschênes, Dandan Yang
article en

Abstract

Background: Cardiomyocytes (CMs) undergo constant mechanical stress during contraction and are vulnerable to membrane damage. Impaired sarcolemmal integrity is a key factor of heart failure progression; hence, strengthening membrane repair represents a promising strategy for cardioprotection. While long non-coding RNAs (lncRNAs) are pivotal in cardiac function and disease, their direct involvement in membrane repair remains largely unexplored. Objective: To identify lncRNAs involved in membrane repair and evaluate their therapeutic potential in ischemic cardiac injury. Methods: Subcellular RNA fractionation (cytosolic, organellar, and plasma membrane) were isolated from heart tissues and sequenced to identify lncRNAs enriched at the plasma membrane (PM). Top candidate lncRNAs were assessed for their role in endocytosis, exocytosis and membrane repair using HL-1 cardiac muscle cells, neonatal CMs, and human induced pluripotent stem cell (iPSC)-differentiated CMs. Intramuscular delivery of lncRNAs was used to evaluate their therapeutic effect in a mouse model of myocardial infarction (MI). Results: Of the top 30 candidate lncRNAs, five PM-enriched lncRNAs were successfully cloned, synthesized, and purified, including Masir (MG53-associated sarcolemma injury repair lncRNA). Gfp RNA served as a control. Masir enhanced both endocytosis and exocytosis in HL-1 cardiac muscle cells. Importantly, rapid extracellular treatment of Masir significantly reduced laser-induced membrane injuries in HL-1 cells and wild-type neonatal CMs but had no effect in MG53-knockout CMs. In vivo, Masir -treated mice demonstrated improved cardiac function post-MI compared to Gfp -treated controls, with higher ejection fraction (34.29% ± 5.36, n=13 vs. Gfp : 21.53% ± 2.64, p =0.047) and significantly smaller scar size. Notably, mouse Masir RNA also attenuated laser-induced membrane injury in hiPSC-derived CMs, highlighting its translational relevance. Conclusion: Masir interacts with MG53, promotes sarcolemmal membrane repair, and confers protection against ischemic injury. These finding demonstrate a direct, functional role for lncRNAs in membrane repair and establish a foundation for RNA-based therapies targeting heart disease.

CirculationVol. 152(Suppl_3)
University of Kentucky (US), The Ohio State University (US)
Openalex Percentile: Top 61%
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.